Showing results (41-50 of 60) with videos related to
Sort By:
Pageof 6
Scientific Reports|October 20, 2018
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancerKaty Teo, Laura Gómez-Cuadrado, Milou Tenhagen, et al.The Journal of Gene Medicine|March 18, 2004
Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4Daniëlle A M Heideman, Victor W van Beusechem, Elisabeth Bloemena, et al.Oncotarget|October 6, 2017
Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female miceJolien S de Groot, Paul J van Diest, Miranda van Amersfoort, et al.The Journal of Clinical Investigation|July 13, 2011
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistanceRon C J Schackmann, Miranda van Amersfoort, Judith H I Haarhuis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatinBastiaan Evers, Rinske Drost, Eva Schut, et al.Cancer Research|June 5, 2013
Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signalingRon C J Schackmann, Sjoerd Klarenbeek, Eva J Vlug, et al.Frontiers in Endocrinology|August 15, 2022
Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesisLieke M van der Velden, Peter Maas, Miranda van Amersfoort, et al.Nature Communications|July 16, 2019
Corrigendum: p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesisRobert A H van de Ven, Jolien S de Groot, Danielle Park, et al.Nature Communications|December 23, 2016
p120-catenin prevents multinucleation through control of MKLP1-dependent RhoA activity during cytokinesisRobert A H van de Ven, Jolien S de Groot, Danielle Park, et al.Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.Pageof 6